ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Reporting Period: Quarter and nine months ended September 29, 2000.
Business Overview: The Company designs and manufactures power sources, capacitors, and components for implantable medical devices (Medical Segment) and commercial power sources for aerospace and oil/gas exploration (Commercial Segment).
Key Event: The Company completed an Initial Public Offering (IPO) in October 2000, shortly after the quarter-end, raising approximately $84.0 million in net proceeds to pay down senior debt.

Key Financial Metrics

Note: Debt figures represent total obligations as of Sept 29, 2000. Significant debt reduction occurred in October 2000 using IPO proceeds.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 19% ($3.7M) for the quarter and 21% ($11.9M) for the nine-month period compared to 1999. Growth was driven by new capacitor product sales and the acquisition of Battery Engineering, Inc. (BEI).
• Margin Compression: Gross margin declined from 50% to 42% (quarter) and 50% to 43% (nine months). This was primarily due to start-up costs associated with the new capacitor line and a higher mix of lower-margin commercial and component products.
• Net Loss Expansion: Net loss widened to $0.9M for the quarter from $0.1M in the prior year quarter, driven by capacitor start-up costs, severance costs from the BEI acquisition, and higher interest expenses.
• Interest Expense: Interest expense increased 12% for the quarter and 17% for the nine months due to higher interest rates, though management expects a significant decrease following the IPO debt paydown.

Guidance, Outlook, and Risks

• Outlook: Management expects interest expense to decrease significantly in future quarters due to the application of $84.0 million in IPO proceeds to outstanding debt. Capacitor revenues are expected to grow at a higher rate than other medical products and become increasingly profitable in 2001.
• Liquidity: The Company believes existing cash, operating cash flow, and working capital funding sources are sufficient for the next two years. The revolving line of credit allows borrowing up to $13.0 million (potentially $20.0 million if targets are met).
• Risks:
  • Customer Concentration: Guidant Corporation (34%) and St. Jude Medical, Inc. (32%) accounted for the majority of revenues in the first nine months of 2000.
  • Patent Expirations: Royalty revenues from Medtronic, Inc. are expected to cease as patents expire in 2000, unless new patents are secured.
  • Product Mix: Continued reliance on start-up costs for new capacitor lines may pressure margins in the short term.
• Unusual Items: The filing includes a subsequent event where the Company purchased $5.0 million of its senior subordinated notes and 127,532 shares of its own stock in October 2000.

Investor Verification Checklist

• IPO Proceeds Application: Verify the exact amount of debt retired using the $84.0 million in IPO proceeds and the resulting impact on the balance sheet in the subsequent 10-Q or 10-K.
• Capacitor Profitability: Monitor the trajectory of capacitor gross margins to confirm the transition from start-up costs to profitability as projected for 2001.
• Customer Concentration: Assess the risk exposure related to the top two customers (Guidant and St. Jude) representing over 65% of revenue.
• Debt Covenants: Confirm continued compliance with financial covenants (EBITDA, leverage ratios) under the revolving line of credit, especially given the historical waiver in 1999.
• Royalty Revenue: Verify if any new patent agreements have been secured to replace the expiring Medtronic royalties.